Esperion announces new drug submissions in Canada for Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) treatments to reduce LDL-cholesterol and cardiovascular risk

2 December 2024 - Esperion today announced that it has filed new drug submissions to Health Canada for Nexletol and Nexlizet, ...

Read more →

Government of Canada signs bilateral agreement with Alberta to improve access to drugs for rare diseases

5 December 2024 - Today, the Honourable Mark Holland, Canada's Minister of Health, and the Honourable Adriana LaGrange, Alberta's Minister ...

Read more →

Canada’s Drug Agency launches consultation on methods guide

28 November 2024 - Canada’s Drug Agency is launching a consultation on its first ever methods guide.  ...

Read more →

Health Canada approves Wegovy (semaglutide injection) to reduce the risk of non-fatal myocardial infarction

27 November 2024 - Wegovy is the first and only medication indicated for both chronic weight management and to reduce the ...

Read more →

BC man calls on federal, provincial governments to cover his costly, life saving cancer treatment

30 November 2024 - Pharmaceutical company Novartis says a five dose treatment costs about $135K. ...

Read more →

Health Canada authorises Carvykti (ciltacabtagene autoleucel) for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy

21 November 2024 - Authorisation is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with ...

Read more →

Lilly Canada remains steadfast in commitment to access options for patients amidst controversial CDA-AMC recommendation for Ebglyss (lebrikizumab)

19 November 2024 - Eli Lilly Canada is disappointed and strongly disagrees with Canada's Drug Agency (CDA-AMC)'s Final Recommendation for Ebglyss ...

Read more →

Novartis Canada disappointed with outcome of pCPA negotiations for metastatic castration resistant prostate cancer treatment Pluvicto

15 November 2024 - Novartis Canada is extremely disappointed that negotiations for Pluvicto (lutetium (Lu 177 ) vipivotide tetraxetan injection), ...

Read more →

Knight Therapeutics announces Health Canada approval for Jornay PM to treat attention deficit hyperactivity disorder

14 November 2024 - Knight Therapeutics announced today that Health Canada has approved Jornay PM, an extended-release formulation of methylphenidate, a ...

Read more →

Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anaemia

12 November 2024 - Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients who have ...

Read more →

Moderna receives Health Canada approval for RSV vaccine for adults aged 60 years and older

8 November 2024 - mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only ...

Read more →

Canada's Drug Agency recommends Winrevair (sotatercept) for reimbursement

8 November 2024 - Merck announced that Canada's Drug Agency has recommended Winrevair (sotatercept) for reimbursement in combination with standard ...

Read more →

Expanded age indication for GSK's Arexvy, the first respiratory syncytial virus vaccine approved in Canada for adults aged 50-59 at increased risk

5 November 2024 - Clinical development program continues to evaluate safety and immunogenicity in adults aged 18-49 at increased risk ...

Read more →

NS parents dismayed by lack of access to new RSV vaccines for infants

3 November 2024 - Officials say there is no universally available, publicly funded RSV vaccine program for newborns in Nova Scotia. ...

Read more →

Differences in drug shortages in the US and Canada

31 October 2024 - In this cross-sectional study, there were 104 reports of drug-related supply chain issues that occurred from 2017 ...

Read more →